DSI Glenwater Dialysis is a medicare approved dialysis facility center in Charlotte, North Carolina and it has 42 dialysis stations. It is located in Mecklenburg county at 9030 Glenwater Drive, Charlotte, NC, 28262. You can reach out to the office of DSI Glenwater Dialysis at (704) 503-6900. This dialysis clinic is managed and/or owned by Diversified Specialty Institutes (dsi). DSI Glenwater Dialysis has the following ownership type - Profit. It was first certified by medicare in April, 1998. The medicare id for this facility is 342591 and it accepts patients under medicare ESRD program.
| Name | DSI Glenwater Dialysis |
|---|---|
| Location | 9030 Glenwater Drive, Charlotte, North Carolina |
| No. of Dialysis Stations | 42 |
| Medicare ID | 342591 |
| Managed By | Diversified Specialty Institutes (dsi) |
| Ownership Type | Profit |
| Late Shifts | No |
| 9030 Glenwater Drive, Charlotte, North Carolina, 28262 | |
| (704) 503-6900 | |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| NPI Number | 1689940108 |
| Organization Name | U.s. Renal Care Glenwater Dialysis |
| Doing Business As | Dialysis Newco Inc |
| Address | 9030 Glenwater Dr Charlotte, North Carolina, 28262 |
| Phone Number | (704) 503-6900 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| NPI Number | 1932118460 |
| Organization Name | Rai-glenwater-charlotte |
| Doing Business As | Rai Care Centers Of North Carolina Ii, Llc |
| Address | 9030 Glenwater Dr Charlotte, North Carolina, 28262 |
| Phone Number | (704) 503-6900 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 66% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 18% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 16% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 55% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 14% |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 45% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 34% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 37% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 34% | 12% |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 71% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 29% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 44% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 12% |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 92 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 26 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 148 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1344 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 9 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 82 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DSI Glenwater Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 166 |
| Hypercalcemia patient months | 1530 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 4 |
| Patients with Serumphosphor | 171 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 35 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 126 |
| Patient months included in arterial venous fistula and catheter summaries | 1124 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 59 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 13 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 139 |
| Hospitalization Rate in facility | 143.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 225.3 |
| Hospitalization Rate: Lower Confidence Limit | 97.7 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at DSI Glenwater Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 27.7 |
| Readmission Rate: Lower Confidence Limit | 15.1 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at DSI Glenwater Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .39 (Better than Expected) |
| SIR: Upper Confidence Limit | .94 |
| SIR: Lower Confidence Limit | .12 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether DSI Glenwater Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 125 |
| Transfusion Rate in facility | 45.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 77.6 |
| Transfusion Rate: Lower Confidence Limit | 28.6 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at DSI Glenwater Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 696 |
| Mortality Rate in facility | 16.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20.4 |
| Mortality Rate: Lower Confidence Limit | 13 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago
Presbyterian Hospital Location: 200 Hawthorne Lane, Charlotte, North Carolina, 28204 Phone: (704) 384-4034 |
Carolinas Medical Center Dialysis Unit Location: 1000 Blythe Blvd, Charlotte, North Carolina, 28232 Phone: (704) 381-7175 |
Fresenius Medical Care Charlotte Location: 928 Baxter Street, Charlotte, North Carolina, 28204 Phone: (704) 348-2950 |
South Charlotte Dialysis Location: 6450 Bannington Road, Charlotte, North Carolina, 28226 Phone: (704) 542-9499 |
Charlotte Dialysis Location: 2321 W Morehead Street, Charlotte, North Carolina, 28208 Phone: (704) 333-5535 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
Equinox Surgical Solutions LLC today announced the launch of their new product, SutureAssist®, designed and developed by a minimally invasive, Board Certified, OB/GYN surgeon Dr. Warren Volker M.D., Ph.D. and his team to improve patient and surgical team safety. This proprietary device lets surgeons and scrub techs acquire, hand-off, dispose of and reload sutures with an efficient, one-handed motion resulting in significantly quicker wound closure and mitigation of both needle-stick risk to the surgical team and post-op needle management liability exposure.
Whether you're a Major League outfielder chasing down a hard-hit ball or a lesser mortal navigating a busy city sidewalk, it pays to keep a close watch on your surroundings when walking or running.
Geron Corporation today reported financial results for the three and six months ended June 30, 2010.
› Verified 9 days ago